

Press Release

For immediate release

**Arvind Remedies Ltd Q2FY15 net sales grows by 34%, at Rs. 293Crore
Registers Rs 1.32crore PAT**

Chennai, November 13th 2014: Arvind Remedies Ltd. (ARL), a leading producer of branded and generic pharmaceutical products announced its financial results for the second quarter and half year ended September 30th 2014.

Key figures

(in Rs. Crore)

Particulars	Q2FY14-15	Q2FY13-14	Growth	H1FY14-15	H1FY13-14	Growth
Net Sales	293	219.49	34%	552	403.12	37%
EBITDA	42	38.11	10%	105	77.34	36%
Net Profit	1.32	13.13	-90%	27	29.66	-9%
EPS	0.19	1.93	-90%	4.03	4.35	-8%

Q2FY14-15 Highlights:

- Net Sales for Q2FY14-15 increased by 34% to Rs. 293crore as compared to Rs. 219crore of Q2FY13-14
- EBIDTA for Q2FY14-15 registered a growth of 10% to Rs. 42crore as compared to Rs. 38crore in Q2FY13-14
- PAT for Q2FY14-15 decreased by 90% to Rs. 1.32crore as against Rs. 13crore in Q2FY13-14

H1FY14-15 Highlights:

- Net Sales for H1FY14-15 increased by 37% to Rs. 552 crore as compared to Rs. 403 crore of H1FY13-14
- EBIDTA for H1FY14-15 registered a growth of 36% to Rs. 105 crore as compared to Rs. 77 crore in H1FY13-14
- PAT for H1FY14-15 decreased by 9% to Rs. 27 crore as against Rs. 30 crore in H1FY13-14

Management Comments:

Our Margins are affected due to the following reasons:

- Higher R&D expenditure is incurred towards development of new drug product for Neuro Degeneration disorder & other chronic diseases during the Current Quarter.
- Due to slow realisation of the receivables, we have arranged temporary short term finance at higher interest rates which have affected our margins.



Press Release**For immediate release**

- Due to increase in maintenance cost of inventory at higher levels to cater the orders.
- Due to Increase in Material Cost.

"However we continue to see improvement in our performance going forward and develop new products. The MoU with Adesh University, Bhatinda, Punjabis showing good signs and we are confident to manufacture side-effect free new drug products that will help in preventing and managing of Neuro Vascular disorder, Metabolic disorder, Irritable Bowel Syndrome and Diabetes."

About Arvind Remedies Ltd:

Arvind Remedies Ltd started in the year 1988 and went public in 1995. The Company is listed on NSE and BSE. ARL has developed a base in the Retail Brand marketing with 30 products. ARL has a significant presence in the Hospital marketing Segment comprising State Government Institutions, Central Government Institutions, Quasi Government Institutions and Corporate Hospitals. The Company has made a mark internationally with its branded and generic formulation. The presence of ARL is seen in South Asia and Africa. The Company has already been undertaking CRAMs for National & Multi-national Pharma Companies. The company's two CGMP-compliance manufacturing facilities are located near Kakkalur and one State-of-the-Art Facility is at Irungattukottai near Chennai and one facility of our Subsidiary Company of Coronet Labs Pvt. Ltd at Roorkee, Uttarakhand. For more Details, Please visit our website www.arvindremedies.com

